Person:
GÜRSU, MELTEM

Loading...
Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
Organizational Unit
Job Title
First Name
MELTEM
Last Name
GÜRSU
Name
Email Address
Birth Date

Search Results

Now showing 1 - 8 of 8
  • PublicationOpen Access
    Comparative Evaluation of Orthostatic Hypotension in Patients with Diabetic Nephropathy.
    (2021-07-20T00:00:00Z) Aytaş, Gamze; Elçioğlu, Ömer C; Kazancıoğlu, Rümeyza; Gürsu, Meltem; Artan, A Serra; Yabacı, Ayşegül; Soysal, PINAR; Bilgi, Kadir; Özçelik, Semra; KAZANCIOĞLU, RÜMEYZA; ELÇİOĞLU, ÖMER CELAL; GÜRSU, MELTEM; YABACI TAK, AYŞEGÜL; SOYSAL, PINAR; ÖZÇELİK, SEMRA
    Introduction: Orthostatic hypotension (OH) affects 5-20% of the population. Our study investigates the presence of OH in diabetic nephropathy (DNP) patients and the factors affecting OH in comparison with nondiabetic chronic kidney disease (NDCKD) patients. Method: Patients presented to the nephrology clinic, and those who consented were included in the study. DNP was defined by kidney biopsy and/or clinical criteria. NDCKD patients of the same sex, age, and eGFR were matched to DNP patients. Demographic parameters and medications were obtained from the records. OH was determined by Mayo clinic criteria. The same researcher used an electronic device to measure blood pressure (BP). All samples were taken and analyzed the same day for biochemical and hematologic parameters and albuminuria. Results: 112 (51 F, 61 M, mean age: 62.56 ± 9.35 years) DNP and 94 (40 F, 54 M, mean age: 62.23 ± 10.08 years) NDCKD patients were included. There was no significant difference between DNP and NDCKD groups in terms of OH prevalence (70.5 vs. 61.7%, p = 0.181). Male patients had significantly higher OH prevalence than female patients (74.7 vs. 60.0%, p = 0.026). There was no significant difference in change in systolic BP between the groups (24.00 [10.00-32.00] mm Hg vs. 24.00 [13.75-30.25] mm Hg, p = 0.797), but the change in diastolic BP was significantly higher in the DNP group (8.00 [2.00-13.00] mm Hg vs. 6.00 [2.00-9.00] mm Hg, p = 0.025). In the DNP group, patients with OH had significantly higher uric acid levels than those without OH (7.18 ± 1.55 vs. 6.36 ± 1.65 mg/dL, p = 0.017). And, 73.7% of patients on calcium channel blockers developed OH (p = 0.015), and OH developed in 80.6% of 36 patients on alpha-blockers (p = 0.049). Conclusion: OH prevalence is very high in CKD, and etiology of CKD does not have a statistically significant effect on the frequency of OH, despite a difference that could be meaningful clinically. Therefore, patients with CKD are checked for OH, with or without concurrent diabetes mellitus. Evaluation of postural BP changes should be a part of nephrology practice.
  • PublicationOpen Access
    Acute kidney injury in Turkey: epidemiological characteristics, etiology, clinical course, and prognosis
    (2022-10-01T00:00:00Z) GÜRSU, Meltem; Yegenaga, Itir; TUĞLULAR, ZÜBEYDE SERHAN; DURSUN, BELDA; GÖKÇAY BEK, SİBEL; Bardak, Simge; ONAN, ENGİN; Demir, Serap; DERİCİ, ÜLVER; DOĞUKAN, AYHAN; Sevinc, Mustafa; KOÇYİĞİT, İSMAİL; Altun, Eda; Haras, Ali Burak; ALTIPARMAK, Mehmet Rıza; TONBUL, HALİL ZEKİ; GÜRSU, MELTEM
    Background: This study aimed to evaluate the etiologies, comorbidities, and outcomes of acute kidney injury (AKI) in Turkey and determine any potential differences among different geographical parts of the country. Methods: This prospective observational study was conducted by the Acute Kidney Injury Working Group of the Turkish Society of Nephrology. Demographical and clinical data of patients with AKI at the time of diagnosis and at the 1st week and 1st, 3rd, and 6th months of diagnosis were evaluated to determine patient and renal survival and factors associated with patient prognosis. Results: A total of 776 patients were included (54.7% male, median age: 67 years). Prerenal etiologies, including dehydration, heart failure, and sepsis, were more frequent than other etiologies. 58.9% of the patients had at least one renal etiology, with nephrotoxic agent exposure as the most common etiology. The etiologic factors were mostly similar throughout the country. 33.6% of the patients needed kidney replacement therapy. At the 6th month of diagnosis, 29.5% of the patients had complete recovery; 34.1% had partial recovery; 9.5% developed end-stage kidney disease; and 24.1% died. The mortality rate was higher in the patients from the Eastern Anatolian region; those admitted to the intensive care unit; those with prerenal, renal, and postrenal etiologies together, stage 3 AKI, sepsis, cirrhosis, heart failure, and malignancy; those who need kidney replacement therapy; and those without chronic kidney disease than in the other patients. Conclusion: Physicians managing patients with AKI should be alert against dehydration, heart failure, sepsis, and nephrotoxic agent exposure. Understanding the characteristics and outcomes of patients with AKI in their countries would help prevent AKI and improve treatment strategies.
  • PublicationOpen Access
    Endothelial Dysfunction and Atherosclerosis in Patients With Autosomal Dominant Polycystic Kidney Disease
    (2021-02-01T00:00:00Z) Büyükbaba, Mitat; Çınar, Ahmet; Tunç, Muhammed; Gürsu, Meltem; Kazancıoğlu, Rümeyza; TUNÇ, MUHAMMED; GÜRSU, MELTEM; KAZANCIOĞLU, RÜMEYZA
    Introduction In this study, we aimed to determine the endothelial dysfunction (ED) and atherosclerosis in patients with autosomal dominant polycystic kidney disease (ADPKD). Materials and methods This study was conducted with 83 subjects (26 male, mean age: 46±11 years) consisted of three groups including ADPKD, hypertension (HT) and healthy control groups. The groups were evaluated in terms of serum endocan and asymmetric dimethylarginine (ADMA) levels, flow-mediated dilatation (FMD), nitroglycerin-mediated dilation (NMD) and carotid intima-media thickness (CIMT). Results Serum endocan and ADMA levels and CIMT were significantly higher while NMD was significantly lower in ADPKD group than control group. FMD and NMD were lower but serum ADMA level was higher in the ADPKD group than HT group; while serum endocan level and CIMT were not significantly different in ADPKD and HT groups. In ADPKD patients, CIMT value and serum endocan and ADMA levels were higher while NMD was lower in patients with eGFR≤60 mL/min/1.73 m2 than patients with eGFR>60 mL/min/1.73 m2. Serum ADMA level was higher and NMD was lower in hypertensive ADPKD patients than non-hypertensive ones. Serum endocan level was higher in ADPKD patients with nephrolithiasis and a negative correlation was detected between serum endocan level and 24-hour urine volume. Conclusions Endothelial dysfunction and atherosclerosis are common conditions in ADPKD patients and it was further reinforced in our study. In order to clarify the relationship between serum endocan level and 24-hour urine volume, which is a remarkable finding in our study, larger studies that including the measurement of urine endocan may be useful.
  • PublicationOpen Access
    COVİD-19 infection in a membranous nephropathy patient treated with rituximab.
    (2020-09-04T00:00:00Z) Elcioglu, Omer Celal; Artan, Ayse Serra; Mirioglu, Safak; Gursu, Meltem; Durdu, Bulent; Koc, Meliha Meric; Okyaltirik, Fatmanur; Gultekin, Mehmet Ali; Kazancioglu, Rümeyza; ELÇİOĞLU, ÖMER CELAL; MİRİOĞLU, ŞAFAK; GÜRSU, MELTEM; DURDU, BÜLENT; MERİÇ KOÇ, MELİHA; OKYALTIRIK, FATMANUR; GÜLTEKİN, MEHMET ALİ; KAZANCIOĞLU, RÜMEYZA
    While COVID-19 pandemic continues to afect our country and most countries in the world, we have to make some changes both in our social life and our approach to healthcare. We have to struggle with the pandemic on one hand and also try to follow up and treat our patients with chronic diseases in the most appropriate way. In this period, one of our group of patients who are challenging us for follow-up and treatment are those who should start or continue to use immunosuppressive therapy. In order to contribute to the accumulation of knowledge in this area, we wanted to report a patient who was followed up with the diagnosis of COVID-19 and had been administered rituximab very recently due to a nephrotic syndrome caused by membranous nephropathy.
  • PublicationOpen Access
    Spontanous Rupture of Renal Pelvis Due to Bladder Globe
    (2021-04-01T00:00:00Z) ARTAN, AYŞE SERRA; GÜRSU, Meltem; SHARIFOV, RASUL; ARTAN, AYŞE SERRA; GÜRSU, MELTEM; SHARIFOV, RASUL
  • PublicationOpen Access
    Correlation of Body Composition Analysis with Anthropometric Measurements in Peritoneal Dialysis Patients
    (2022-01-01T00:00:00Z) ARTAN, AYŞE SERRA; GÜRSU, Meltem; ELÇİOĞLU, Ömer Celal; YABACI TAK, AYŞEGÜL; KAZANCIOĞLU, Rümeyza; ARTAN, AYŞE SERRA; GÜRSU, MELTEM; ELÇİOĞLU, ÖMER CELAL; YABACI TAK, AYŞEGÜL; KAZANCIOĞLU, RÜMEYZA
    Objective: This study investigates correlations between different methods for diagnosis of protein energy malnutrition (PEM) in peritoneal dialysis patients. Methods: Twenty four patients were included. Patients with amputations, infections, peritonitis, malignancies and PD duration less than three months were excluded. Physical examination findings, laboratory results and anthropometric measurements were recorded. Body composition analysis was performed with multi-frequency bioimpedance analyzer. Dialysis malnutrition score (DMS) was calculated. The correlations of different parameters were searched. Results: Eleven patients were female and 13 patients were male. Mean age was 58.9±12.6 years. Median dialysis duration was 25 (interquartile range: 14) months. Protein percentage was negatively correlated with fat percentage (r=-0.785; p<0.001), triceps skinfold thickness (SFT) (r=-0.641; p<0.001), biceps SFT (r=-0.685; p<0.001), body mass index (BMI) (r=-0.867; p<0.001), mid-arm circumference (r=-0.680; p=0.001). Fat percentage was positively correlated with BMI (r=0.780; p<0.001), biceps SFT (r=0.817; p<0.001), triceps SFT (r=0.901; p<0.001) and mid-arm circumference (r=0.558; p=0.005) Albumin was negatively correlated with DMS (r= -0.439; p=0.032). DMS and albumin were not correlated with bioimpedance and anthropometry Conclusion: Albumin is a marker of PEM in PD patients. Malnutrition scores may be used as adjunct methods. Increase in fat mass and percentage may influence the interpretation of anthropometric measurements.
  • PublicationOpen Access
    Evaluation of Kidney Function in Patients on Chemotherapy
    (2021-04-01T00:00:00Z) Haziyev, Elgun; GÜRSU, Meltem; ŞEKER, Mesut; ELÇİOĞLU, Ömer Celal; ARTAN, AYŞE SERRA; ALİYEV, Altay; TÜRK, HACI MEHMET; DEMİR, Tarık; TOPRAK, ALİ; KAZANCIOĞLU, Rümeyza; GÜRSU, MELTEM; ŞEKER, MESUT; ELÇİOĞLU, ÖMER CELAL; ARTAN, AYŞE SERRA; ALİYEV, ALTAY; TÜRK, HACI MEHMET; DEMİR, TARıK; TOPRAK, ALİ; KAZANCIOĞLU, RÜMEYZA
    Objective: We aimed to study whether long-term kidney function would be affected by different chemotherapy regimens in patients with malignancy.
  • PublicationOpen Access
    Evaluation of Outcomes of Peritoneal Dialysis Patients in the Post-COVID-19 Period: A National Multicenter Case-Control Study from Turkey
    (2022-05-01T00:00:00Z) ÖZTÜRK, Savaş; Gursu, Meltem; Arici, Mustafa; Sahin, Idris; Eren, Necmi; Yilmaz, Murvet; Ozberk, Sumeyra; Sirali, Semahat Karahisar; Ural, Zeynep; Dursun, Belda; Yuksel, Enver; Uzun, Sami; Sipahi, Savas; Dal, Elbis Ahbap; Yazici, Halil; Altunoren, Orcun; Tunca, Onur; Ayar, Yavuz; Oguz, Ebru Gok; Yilmaz, Zulfikar; Kahvecioglu, Serdar; Asicioglu, Ebru; Oruc, Aysegul; Ataman, Rezzan; Aydin, Zeki; Huddam, Bulent; Dolarslan, Murside Esra; Azak, Alper; Bakirdogen, Serkan; Yalcin, Ahmet Ugur; Karadag, Serhat; Ulu, Memnune Sena; Gungor, Ozkan; Bakir, Elif Ari; Odabas, Ali Riza; Seyahi, Nurhan; Yildiz, Alaattin; Ates, Kenan; GÜRSU, MELTEM
    Introduction: There are not enough data on the post-CO-VID-19 period for peritoneal dialysis (PD) patients affected from COVID-19. We aimed to compare the clinical and laboratory data of PD patients after COVID-19 with a control PD group. Methods: This study, supported by the Turkish Society of Nephrology, is a national, multicenter retrospective case-control study involving adult PD patients with confirmed COVID-19, using data collected from April 21, 2021, to June 11, 2021. A control PD group was also formed from each PD unit, from patients with similar characteristics but without COVID-19. Patients in the active period of COVID-19 were not included. Data at the end of the first month and within the first 90 days, as well as other outcomes, including mortality, were investigated. Results: A total of 223 patients (COVID-19 group: 113, control group: 110) from 27 centers were included. The duration of PD in both groups was similar (median [IQR]: 3.0 [1.88-6.0] years and 3.0 [2.0-5.6]), but the patient age in the COVID-19 group was lower than that in the control group (50 [IQR: 40-57] years and 56 [IQR: 46-64] years, p < 0.001). PD characteristics and baseline laboratory data were similar in both groups, except serum albumin and hemoglobin levels on day 28, which were significantly lower in the COVID-19 group. In the COVID-19 group, respiratory symptoms, rehospitalization, lower respiratory tract infection, change in PD modality, UF failure, and hypervolemia were significantly higher on the 28th day. There was no significant difference in laboratory parameters at day 90. Only 1 (0.9%) patient in the COVID-19 group died within 90 days. There was no death in the control group. Respiratory symptoms, malnutrition, and hypervolemia were significantly higher at day 90 in the COVID-19 group. Conclusion: Mortality in the first 90 days after COVID-19 in PD patients with COVID-19 was not different from the control PD group. However, some patients continued to experience significant problems, especially respiratory system symptoms, malnutrition, and hypervolemia.